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Human cytomegalovirus (HCMV), a clinically important β-herpesvirus, is amaster of evasion
and modulation of the host immune system, including inhibition of a number of dendritic
cell (DC) functions. DCs play a central role in co-ordination of the immune response against
pathogens and any disturbance of DCs functions can result in a cascade effect on a range of
immune cells. Recently, the HCMV gene UL111A, which encodes viral homologs of human
interleukin 10, has been identiﬁed as a strong suppressor of a number of DCs functions.
In this mini review, we focus on HCMV-encoded viral IL-10-mediated inhibitory effects on
DCs and implications for the development of an effective HCMV vaccine.
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HUMAN CYTOMEGALOVIRUS
Human cytomegalovirus (HCMV) is a species-speciﬁc
β-herpesvirus that infects a majority of the world’s population.
Primary HCMV infection in the immunocompetent host is gen-
erally asymptomatic, with a minority of persons experiencing
HCMV induced mononucleosis. However, in immunocompro-
mised patients, such as allogeneic stem cell and solid organ
transplant recipients and HIV/AIDS patients, HCMV infection
results in severe disease affecting multiple organs that can be fatal
(Mocarski et al., 2013). Furthermore, HCMV is themost common
viral congenital infection which can lead to permanent disability
such as hearing loss, mental retardation, and neurological defects
(Kenneson and Cannon, 2007).
Following primary infection, HCMV establishes a life-long
latent infection within myeloid progenitor cells. These precursor
cells can then differentiate into a number of immune cell types
including, monocytes, macrophages and dendritic cells (DCs),
that play a vital role in functions such as antigen presentation lead-
ing to pathogen control and clearance (Reeves and Sinclair, 2008).
During latency the virus persists without detectable replication;
however, HCMV periodically reactivates from latent infection,
resulting in production and shedding of infectious virus, and
this process is most clinically important in immunosuppressed
patients, particularly in allogeneic stem cell and solid organ trans-
plant recipients, in which reactivating virus is the major cause of
serious disease.
Human cytomegalovirus consists of a large, double-stranded
DNA genome that encodes a range of immunomodulatory genes
which function to limit both innate and adaptive host immunity.
Such functions are likely to contribute to the lifelong persistence
that follows primary infection that is characteristic of HCMV
infection. In particular, HCMV encodes a number of soluble
molecules that are homologs of host encoded cytokines and
chemokines (McSharry et al., 2012). The best characterized of
these proteins is the viral homolog of human IL-10 for which a
range of immunomodulatory functions have been identiﬁed, and
is the focus of this review.
HCMV-ENCODED HOMOLOGS OF HUMAN
INTERLEUKIN 10
The human cytokine interleukin 10 (hIL-10) is a master regulator
of the immune response, controlling functions of a number of
different immune cell types (Moore et al., 2001). hIL-10 has par-
ticularly potent and varied effects on DCs. DC exposure to hIL-10
reduces their ability to activate and maintain immune responses,
marked by suppression of pro-inﬂammatory cytokine produc-
tion, expression of MHC class II and co-stimulatory molecules,
DC maturation and ability to stimulate T cells (Hawrylowicz and
O’Garra, 2005). The importance of IL-10 (either host cellular
IL-10 or viral homologs of IL-10) in modulating DC function
and controlling the anti-viral immune response is exempliﬁed by
the range of viruses infecting humans that either induce hIL-10
(e.g., HIV and hepatitis C virus; Reiser et al., 1997; Brockman
et al., 2009) or encode their own homologs of this cytokine (e.g.,
Epstein Barr Virus and some cytomegaloviruses; Slobedman et al.,
2009).
The HCMV gene UL111A encodes two viral homologs of
human interleukin 10 (hIL-10); cmvIL-10 and LAcmvIL-10 that
are both splice variants of the UL111A transcript. cmvIL-10 was
identiﬁed ﬁrst (Kotenko et al., 2000; Lockridge et al., 2000). This
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homolog shares only 27% amino acid identity with hIL-10, how-
ever, despite low homology with hIL-10, cmvIL-10 binds strongly
and can signal through the hIL-10 receptor (Kotenko et al., 2000;
Jones et al., 2002). LAcmvIL-10 is the second viral homolog of
hIL-10 encoded by UL111A that has a truncated C-terminus
due to alternative splicing (Jenkins et al., 2004), and together
with cmvIL-10 makes up HCMV-encoded viral IL-10. Through
intensive research activities of a number of groups over the last
decade, a signiﬁcant amount of data has been published demon-
strating strong immunomodulatory functions of these viral IL-10
homologs on a range of human immune cells including DCs,
monocytes, macrophages, and B cells (Spencer et al., 2002, 2008;
Chang et al., 2004; Raftery et al., 2004; Yamamoto-Tabata et al.,
2004; Jenkins et al., 2008; Cheung et al., 2009; Jaworowski et al.,
2009; Slobedman et al., 2009; Avdic et al., 2011, 2013; McSharry
et al., 2012). This review will principally focus on the effects
of HCMV-encoded viral IL-10 on the function of DCs; cells
often referred to as the sentinels of immunity, due to their
exceptional ability to stimulate the immune response against
pathogens.
DC MODULATION BY HCMV-ENCODED HOMOLOGS OF hIL-10
Dendritic cells play a central role in linking and co-ordination of
the innate and adaptive immune responses against foreign anti-
gens. The DC family can be broadly divided into classical DCs
(cDCs) which are comprised of Langerhans cells (LC), myeloid
DCs and plasmacytoid DCs (pDCs; Caux et al., 1996; Grouard
et al., 1997; Merad et al., 2013). Upon antigen encounter, imma-
ture cDCs undergo the maturation process, where they migrate to
lymph nodes, process and present antigens via MHC class I and
class II to prime CD8+ and CD4+ T lymphocytes, and also pro-
duce cytokines that further orchestrate an effective host immune
response (De Smedt et al., 1996; Merad et al., 2013). Due to tech-
nological advances in ﬂow cytometry and identiﬁcation of novel
cell surface markers over the last 10–15 years, new subsets of cDCs
are continuing to be identiﬁed (Kim et al., 2014) and have been
recently reviewed elsewhere (Merad et al., 2013). pDCs, on the
other hand, represent amuch smaller DC population that respond
to initial viral stimuli primarily by strong production of the anti-
viral cytokine, interferon alpha (IFN-α), but also retain the ability
to prime T cells (Colonna et al., 2004).
Human cytomegalovirus infection has been shown to involve
direct interaction with DCs at a number of levels. Firstly, HCMV
has been demonstrated to infect both immature and mature
DCs in vitro (Jahn et al., 1999; Riegler et al., 2000; Moutaftsi
et al., 2002; Hertel et al., 2003). Secondly, HCMV can latently
infect DC precursors (Hahn et al., 1998) and DCs have been
identiﬁed as a site of HCMV reactivation from natural latent
infection (Reeves et al., 2005; Reeves and Sinclair, 2013). It there-
fore comes as little surprise that HCMV has developed multiple
strategies to inhibit a range of DC functions with an ultimate
goal of limiting or preventing virus clearance by the immune
system. While some aspects of this multi-targeted approach of
DC modulation by HCMV have been characterized (e.g., distur-
bance of MHC class I and class II antigen presenting pathways
by products of HCMV genes US2-11; Jones et al., 1996; Wiertz
et al., 1996; Ahn et al., 1997; Machold et al., 1997; Tomazin et al.,
1999), not all of HCMV-driven modulatory effects on DCs have
been assigned to speciﬁc HCMV gene functions (Sinclair, 2008;
Rolle and Olweus, 2009). However, it has become increasingly
apparent that a number of DC functions are regulated by viral
IL-10.
The ﬁrst evidence of an HCMV-encoded IL-10 targeting DC
function was reported by Peter Barry’s group. Utilizing super-
natants harvested from either infections with a UL111A deletion
mutant virus or the parental (viral IL-10-expressing) HCMV
strain, they identiﬁed that HCMV-encoded viral IL-10 plays
an important role in regulating DC maturation (Chang et al.,
2004). Indeed, progression of immature monocyte derived DCs
(MDDCs), representing an in vitro model of cDC (Sallusto and
Lanzavecchia, 1994), into the mature phenotype induced by
lipopolysaccharide (LPS) was prevented by culture supernatants
from cells infected with parent virus but not from supernatants
from cells infected with the UL111A deletion mutant. Inhibi-
tion of DC maturation by cmvIL-10 protein is accompanied by
suppression of pro-inﬂammatory cytokine synthesis by recom-
binant cmvIL-10 protein, whereas the LAcmvIL-10 protein did
not exert this effect on DCs (Chang et al., 2004; Jenkins et al.,
2008). Similarly, cmvIL-10 (but not LAcmvIL-10) suppresses a
range of MDDC surface co-stimulatory molecules: CD80, CD83,
CD86, and CD40, which are required for efﬁcient T cell acti-
vation (Raftery et al., 2004; Jenkins et al., 2008). These studies
not only demonstrated profound suppression of DC matura-
tion by HCMV-encoded IL-10, but also highlighted a divergence
in the functions of cmvIL-10 and LAcmvIL-10, showing that
LAcmvIL-10 retains some (e.g., suppression of cell surface MHC
class II complex expression required for antigen presentation to
CD4+ T cells) but not all functions of cmvIL-10 (Jenkins et al.,
2008).
In addition to limiting the ability of cmvIL-10 treated cDCs to
efﬁciently stimulate immune responses, exposure of mature cDCs
to cmvIL-10 (and hIL-10) also results in rapid cell apoptosis via
suppressing the induction of anti-apoptotic genes bcl-2, bcl-x, and
bﬂ-1 (Chang et al., 2007). Such effects are likely to limit the time-
frame of antigen presentation and stimulation of T cells by cDCs
exposed to cmvIL-10. A study by Raftery et al. (2004) similarly
reported that cmvIL-10-induced cDC apoptosis in the presence of
an inﬂammatory signal, which was linked to a reduction of anti-
apoptotic c-FLIPL mRNA expression. This comprehensive study
also reported several other mechanisms of cmvIL-10-driven con-
trol of cDC functions, including partial suppression of MHC class
I and class II as well as co-stimulatory molecules B7-H1 and B7-
DC, ultimately resulting in suppressed ability of cmvIL-10-treated
cDCs to induce proliferation of both allogeneic and autologous
T cells (Raftery et al., 2004). Adding to this, cmvIL-10 also sup-
presses transcription of CD1 non-classical MHC class I molecules
that are involved in presentation of lipids rather than peptides
(Raftery et al., 2008).
Decreased cDC stimulatory activity is not due to suppression
of antigen uptake by cmvIL-10-exposed cDCs. Rather, cmvIL-10
appears to actually stimulate antigen uptake in immatureMDDCs
(Raftery et al., 2004). This study also reported that surface expres-
sion of indoleamine 2,3-dioxygenase (IDO) was stimulated by
cmvIL-10. IDO functions to suppress T cell responses by depletion
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of tryptophan (Hwu et al., 2000) and it has been suggested that
IDO expressing cDCs may be involved in induction of T cell
anergy (Munn et al., 2002). While it remains to be examined
in an experimental setting, it is possible that increased antigen
uptake by cmvIL-10-treated IDO expressing cDCs may lead to
an increased proportion of HCMV antigens presented by IDO+
cDCs that could lead to an increased anergic role of anti-HCMVT
cells.
The inhibitory effects of cmvIL-10 are not limited to cDC.
cmvIL-10 released from HCMV-infected cells also effectively sup-
presses IFN-αmRNA transcription and protein synthesis by pDCs
(Chang et al., 2009). This is biologically important in the context of
HCMV infection as IFN-α stimulates other immune cells to clear
the virus but also protects the same immune cells from HCMV
infection (Chang et al., 2009).
Human cytomegalovirus establishes latent infection in CD34+
myeloid progenitors, which can differentiate into DCs or mono-
cyte/macrophages. mRNA expression from the viral IL-10-
encoding HCMV gene UL111A has been detected during experi-
mental as well as natural HCMV latent infection (Jenkins et al.,
2004; Cheung et al., 2006), and work using UL111A deletion
viruses has shown that UL111A gene products suppress a number
of immunostimulatory functions during HCMV latency. Firstly,
surface MHC class II expression levels in myeloid progenitors
latently infected with a parental, viral IL-10-expressing virus, are
signiﬁcantly lower than in progenitors infected with a UL111A
deletion virus (Cheung et al., 2009). Consequently, stimulation
of both allogeneic and autologous CD4+ T cell proliferation by
progenitors carrying latent virus able to express viral IL-10 is
notably suppressed compared to counterparts latently infected
with the UL111A deletion virus (Cheung et al., 2009). Apart
from their inability to prime CD4+ T cell responses, latently
infected myeloid progenitors are also restricted by viral IL-10
in their ability to differentiate into myeloid DCs and LCs, with
noted absence of pro-inﬂammatory cytokine expression by cells
infected with the virus capable of expressing viral IL-10 (Avdic
et al., 2011).
In addition to differentiation to DCs, myeloid progenitors
can also differentiate into monocytes and macrophages which
can act in antigen presenting roles. However, it appears that
even these cells are impacted by viral IL-10, as exposure of
these cells to viral IL-10 results in promotion of deactivated
M2cmonocytes/macrophages, rather than the classically activated,
pro-inﬂammatory M1 type. This impact of viral IL-10 on mono-
cyte/macrophage programming results in impairment of effective
priming and proliferation of CD4+ T cells (Avdic et al., 2013).
Whilst viral IL-10 appears to minimize various DC func-
tions required to instruct the immune system to clear the
virus, this viral cytokine has also been reported to increase
surface expression of DC-SIGN on immature MDDCs (Raftery
et al., 2004). DC-SIGN is a lectin expressed on the cell sur-
face of immature DCs and has been identiﬁed as a potential
receptor for HCMV entry (Halary et al., 2002). Although it
remains to be determined whether viral IL-10 plays any role
in HCMV infection of DCs, it is possible that any viral IL-10-
mediated upregulation of DC-SIGNmay enhance virus entry into
DCs.
BLOCKING VIRAL IL-10: POTENTIAL HCMV VACCINE
STRATEGY
The quest to develop a HCMV vaccine has been underway
for>40 years (Elek and Stern, 1974). To this date, however, there
is still no licensed HCMV vaccine. Multiple factors have com-
plicated the development of an effective HCMV vaccine, with a
signiﬁcant limitation being the strict host speciﬁcity of HCMV,
limiting the use of pre-clinical animal models to evaluate vaccine
efﬁcacy.
As already discussed, DCs are a critical component of the
orchestrated immune response to pathogens that form a link
between innate and adaptive immunity. For that reason, it is an
imperative to ensure that DCs function at their best, instruct-
ing the immune system during initial response to vaccination
and during subsequent challenge with live pathogens. Given
that HCMV-encoded viral IL-10 severely alters DC functions,
it could be argued that viral IL-10 expressed by any live atten-
uated HCMV vaccine candidate may limit the host’s immune
response toward such a vaccine. Indeed, several recent stud-
ies have investigated the role of viral IL-10 in the development
of a vaccine against HCMV. Due to strict species speciﬁcity of
HCMV, these studies have relied upon a rhesus macaque ani-
mal model, whereby rhesus monkeys are infected with rhesus
CMV (RhCMV), which also encodes a viral IL-10. It is impor-
tant to note that murine cytomegalovirus (MCMV) does not
encode its own IL-10 homolog and this has limited the study
of cytomegalovirus encoded IL-10 in more common animal
models.
Two approaches have been utilized to investigate immune
responses when the expression of viral IL-10 is blocked or
modiﬁed. Firstly, it has been demonstrated that the blockade
of RhCMV-encoded viral IL-10 expression (using a viral IL-10
knockout virus) during RhCMV infection in vivo resulted in a
signiﬁcant increase in DC numbers in draining lymph nodes and
stronger CD4+ T cell proliferation, as well as higher IgG titers
(Chang and Barry, 2010). This study provided evidence that appli-
cation of any live attenuatedHCMV vaccinemay bemore effective
at inducing anti-viral immunity if it contains targeted disruption
of the viral IL-10 locus.
Secondly, it is known that antibodies are produced against viral
IL-10 in both humans and rhesus macaques and that these can
neutralize viral IL-10 function (de Lemos Rieper et al., 2011; Eber-
hardt et al., 2012). Therefore, blocking expression of viral IL-10
through gene deletion may limit a potential target of an effective
immune response. An alternative approach to develop a vaccine
whereby mutated versions of viral IL-10 unable to bind to the
IL-10R but still able to stimulate production of anti-viral IL-10-
neutralizing antibodies has also been investigated. Immunization
of seronegative animals with mutated forms of viral IL-10 prior
to challenge with RhCMV resulted in decreased viral replication
both locally (at the site of RhCMV infection) and systemically
(with reduced viral shedding in bodily ﬂuids; Logsdon et al., 2011;
Eberhardt et al., 2013).
Collectively, these data demonstrate that abrogating the
immunosuppressive functions of viral IL-10, whilst still enabling
generation of anti-viral IL-10 antibody, may be an important
component in the design of an effective vaccine against HCMV.
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CONCLUSION
Viral IL-10 encoded by HCMV UL111A employs a multi-targeted
approach to profoundly modulate DC functions. It decreases DC
differentiation from progenitor cells and DC maturation from
immature DCs. Suppression of antigen presenting molecules
(MHC class I and class II) together with suppression of co-
stimulatory molecules both work together to reduce priming and
proliferation of T cells. Additionally, viral IL-10 also suppresses
secretion of pro-inﬂammatory cytokines, which is likely to add
to repression of the immune response. Viral IL-10 can reduce the
ability of DCs to present antigen via inhibition of anti-apoptotic
factors but also potentially drives DCs toward a phenotype that
could induce T cell anergy and therefore render the adaptive
immune response less responsive to the virus infection. Together
with other immunommodulatory genes encoded by HCMV, the
impact of viral IL-10 onDCs is likely to create an environment that
beneﬁts the virus by limiting virus clearance by the host immune
system.
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